What is galactomannan and how is it used to diagnose invasive aspergillosis in immunocompromised patients?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 21, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What is Galactomannan?

Galactomannan is a polysaccharide component of the Aspergillus cell wall that is released into circulation during fungal growth and serves as a highly sensitive and specific biomarker for diagnosing invasive aspergillosis in immunocompromised patients. 1, 2

Structure and Detection

  • Galactomannan (GM) is a polysaccharide antigen located in the cell wall structure of Aspergillus species that is released by growing hyphae into the host's bloodstream and other body fluids. 2, 3

  • The antigen is detected using an enzyme-linked immunosorbent assay (ELISA), commercially available as Platelia® Aspergillus, which measures galactomannan concentration as an optical density index (ODI). 1

Diagnostic Performance in High-Risk Patients

In granulocytopenic and hematologic malignancy patients, galactomannan ELISA demonstrates 80-100% sensitivity and 90-100% specificity, with a negative predictive value exceeding 90% for excluding invasive aspergillosis. 1, 4

  • The test performs optimally when two consecutive serum samples show an ODI ≥0.5, which is the current recommended cut-off for positivity. 1, 4

  • At the 0.5 ODI threshold, sensitivity is 82% and specificity is 81%; increasing the cut-off to 1.5 ODI improves specificity to 93% but reduces sensitivity to 61%. 5

  • Galactomannan may become positive before clinical suspicion of infection arises, enabling pre-emptive diagnosis and earlier treatment initiation. 1

Testing Strategy and Frequency

  • Testing should be performed at least twice weekly (every 3-4 days) in high-risk patients because galactomannan circulation is transient. 1, 4

  • Routine screening is recommended for patients with hematologic malignancies, neutropenia, hematopoietic stem cell transplant recipients, and solid organ transplant recipients. 4

  • The test can detect galactomannan from several Aspergillus species, not just Aspergillus fumigatus. 1

Detection in Other Body Fluids

  • Galactomannan detection in bronchoalveolar lavage (BAL) fluid is superior to serum testing for localized pulmonary disease, with sensitivity of 80-100% and optimal cut-off values between 0.5 and 1.0 ODI. 4, 6

  • In cerebrospinal fluid (CSF), galactomannan detection appears superior to culture and some PCR assays for identifying CNS aspergillosis. 1

  • BAL fluid testing is strongly recommended when serum galactomannan is negative but clinical suspicion remains high. 4

Critical Limitations: False Positives

False-positive results occur in up to 8% of blood samples, most commonly in patients receiving piperacillin-tazobactam or other β-lactam antibiotics. 1, 6

  • Antibiotic interference accounts for 50-58.3% of false-positive BAL galactomannan results. 6

  • Other causes of false positivity include infection with non-Aspergillus fungi and certain food products. 7

  • Despite potential false positives, high-risk patients with positive galactomannan should be treated immediately given the high mortality of untreated invasive aspergillosis. 6

Role in Therapeutic Monitoring

  • Serial galactomannan testing can facilitate therapeutic monitoring, with progressive decreases in ODI during the first two weeks predicting satisfactory treatment response. 1, 8, 6

  • However, duration of therapy should be determined by resolution of clinical and radiological findings, not solely by normalization of galactomannan antigenemia. 1

  • The use of serial galactomannan for therapeutic monitoring remains investigational. 1

Clinical Impact on Diagnosis

  • Introduction of routine galactomannan testing significantly increases detection rates of invasive aspergillosis compared to conventional culture-based methods alone. 9

  • The test is particularly valuable when invasive diagnostic procedures (bronchoscopy, biopsy) are contraindicated due to thrombocytopenia, coagulopathy, or hemodynamic instability. 1

Not Recommended For

Galactomannan testing is NOT recommended for diagnosing allergic bronchopulmonary aspergillosis (ABPA) due to poor diagnostic accuracy in this non-invasive condition. 1

  • Routine Aspergillus antibody testing is also not recommended in immunocompromised patients, as antibodies are frequently undetectable in this population. 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Diagnosing Aspergillosis with Blood Tests

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Galactomannan detection for invasive aspergillosis in immunocompromised patients.

The Cochrane database of systematic reviews, 2015

Guideline

Management of Positive BAL Galactomannan

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Diagnosis of invasive aspergillosis by galactomannan antigenemia detection using an enzyme immunoassay.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2008

Guideline

Treatment of Invasive Aspergillosis with Bowel Wall Thickening

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.